Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Anticancer Properties of Natural and Derivative Products
| Anticancer Properties of Natural and Derivative Products |
| Autore | Lupiáñez José Antonio |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
| Descrizione fisica | 1 electronic resource (312 p.) |
| Soggetto topico | Research & information: general |
| Soggetto non controllato |
total phenolic content
total flavonoid content GC-MS DPPH antioxidant anticancer agent anti-inflammatory agent gingival fibroblasts oral cancer natural extract Adenosma bracteosum extract anti-cancer cell line isolated compounds caspase-3 bioactive compounds metabolites wine grapes breast cancer chemoprevention chemotherapy squamous cell carcinoma Moringa oleifera 3-hydroxy-β-ionone antioxidant activity antioxidant enzymes anti-proliferative activity maslinic acid melanoma Olea europaea L. ROS levels photodynamic therapy cancer photosensitiser natural compounds Elaeagnus angustifolia EMT apoptosis AKT/PI3K signaling pathway human hepatocarcinoma HepG2 cells migration activity proliferation oxidative stress ROS level uvaol lung metastases in vivo complementary medicine medicinal mushrooms triterpenoic acid tormentic acid betulinic acid oleanolic acid rhodamine B cytotoxicity hepatocellular carcinoma (HCC) Pogostemon cablin (PPa extract) cell cycle synergism natural photosensitive compounds anticancer activity hypericin emodin quinizarin danthron interaction DNA glioblastoma (GBM) lactucopicrin (LCTP) temozolomide (TMZ) autophagy NF-κB p62/SQSM1 natural product therapeutic triglyceride xenograft study Caveolin-1 actin cytoskeleton betulin glycoconjugates click chemistry 1,3-dipolar cycloaddition |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557370303321 |
Lupiáñez José Antonio
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination
| Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination |
| Autore | Alix-Panabieres Catherine |
| Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (366 p.) |
| Soggetto non controllato |
FOLFIRINOX
immunofluorescence imaging AR-V7 circulating tumour cells chemoradioresistance CTC-based treatment decisions rVAR2 immunophenotyping immune system CellSearch® flow cytometry clinical trials circulating tumor DNA synaptophysin stem cells colorectal cancer melanoma CTC biology platelets AR CTC capture technology castration resistant prostate cancer (CRPC) PD-L1 expression rovalpituzumab tesirine HMB-45 thymidylate synthase ctDNA tumor cell dissemination solid cancers metastasis locally advanced rectal cancer miRNA epithelial-to-mesenchymal transition (EMT) NSCLC tumor biomarkers tumor stem cells circulating tumor cells major histocompatibility complex class I (MHCI) bone marrow heterogeneity cerebrospinal liquid biopsy fish glioma in vivo flow cytometry colorectal surgery CellSearch single-cell analysis disseminated tumor cells EasyCount slides microsatellite instability circulating plasma cells circulating leukemia cells ARV7 SLUG androgen receptor metastatic colorectal cancer leukocyte-derived extracellular vesicles prostate cancer (PCa) neutrophils liquid biopsy enzalutamide CD133 enrichment and detection technologies biomarkers immune checkpoint inhibitors biomarker RAD23B microbiome integrin B1 ACCEPT emboli small-cell lung carcinoma EPISPOT microfluidics early breast cancer circulating tumor cells (CTC) tumor-initiating cells (TICs) immunomodulation xenograft models CTC-derived xenografts malaria circulating tumor cells (CTCs) clinical utility exosomes liquid surgery ctRNA CTCs epithelial-mesenchymal transition targeted therapy hematological cells gene expression analysis hepatocellular carcinoma (HCC) breast cancer EpCAM enrichment prostate cancer CTC abiraterone fibronectin CTC-derived ex vivo models CTMat chromogranin A CTM exosome |
| ISBN | 3-03928-699-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Circulating Tumor Cells |
| Record Nr. | UNINA-9910404091403321 |
|
Alix-Panabieres Catherine
|
||
| MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges
| Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges |
| Autore | Gabazza Esteban C |
| Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2019 |
| Descrizione fisica | 1 electronic resource (348 p.) |
| Soggetto non controllato |
bleomycin
regeneration antitumor efficacy lung cancer SOX2 leiomyosarcoma lung cancer (LC) nanoparticles cytokines hepatocellular carcinoma metabolic reprogramming hepatic stellate cells angiogenesis transforming growth factor-? anaplastic lymphoma kinase idiopathic pulmonary fibrosis growth factor pathogenesis cancer-associated fibroblasts fibrosis lipopolysaccharide DHA lncRNA SREBP-1 YAP protein S non-small cell lung cancer (NSCLC) omega-3 fatty acid inflammation metastasis clinical symptoms miRNA smooth muscle tumor of uncertain malignant potential Wnt interstitial fluid pressure heterogeneity hepatocytes myometrium tumor necrosis factor ? tumor tumor microenvironment extracellular matrix TAZ carcinogenesis cystic formation pulmonary fibrosis HBV cytokine genetic instability diagnosis EMT crizotinib Hippo pathway GPR120 marker HCV non-alcoholic steatohepatitis pathology common pathways apoptosis type I collagen GPR40 acute lung injury uterine fibroid renal injury pathophysiology reactive oxygen species immunohistochemistry SMAD butylidenephthalide leiomyoma cirrhosis Erk1/2 targeted therapy TGF-? mechanotransduction therapy breast cancer hepatocellular carcinoma (HCC) hepatic stellate cells (HSCs) idiopathic pulmonary fibrosis (IPF) cancer-associated fibroblasts (CAFs) cancer signal pathway tumor stiffness |
| ISBN | 3-03921-707-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Links between Fibrogenesis and Cancer |
| Record Nr. | UNINA-9910367745903321 |
|
Gabazza Esteban C
|
||
| MDPI - Multidisciplinary Digital Publishing Institute, 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Targeting STAT3 and STAT5 in Cancer
| Targeting STAT3 and STAT5 in Cancer |
| Autore | Moriggl Richard |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (578 p.) |
| Soggetto topico |
Research & information: general
Biology, life sciences |
| Soggetto non controllato |
multiple myeloma
STAT3 S3I-1757 nanoparticle CD38 siRNA/RNAi polyethylenimine PEI lipopolyplex siRNA delivery glioma glioblastoma STAT5 AKT ERK1/2 prolactin androgens prostate cancer knockout escape mechanisms stem/progenitor cells cell hierarchy cancer CD4+ T cells CD8+ T cells myeloid cells immune check point hepatitis C virus (HCV) cirrhosis hepatocellular carcinoma (HCC) endoplasmic reticulum (ER) stress oxidative stress (OS) unfolded protein response (UPR) microRNA-122 (miR-122) nuclear factor erythroid 2-related factor 2 (NRF2) signal transducer and activator of transcription 3 (STAT3) hepatocyte nuclear factor 4 alpha (HNF4A) solid cancers cell cycle apoptosis inflammation mitochondria stemness tumor suppression melanoma autoimmune disease immunotherapy tumor-immune cell interactions breast cancer PD-L1 M2 macrophages NK cells STAT3 inhibitor XIII hedging transaction costs dynamic programming risk management post-decision state variable cancer progression cancer-stem cell cytokine therapy resistance metastasis immunosuppression tumor microenvironment proliferation tyrosine kinase 2 JAK family of protein tyrosine kinases signal transducer and activator of transcription cytokine receptor signaling gain-of-function mutation tumorigenesis ADAM17 interleukin-6 trans-signaling epidermal growth factor receptor (EGF-R) shedding metalloprotease tumor necrosis factor alpha (TNFα) inflammation associated cancer colon cancer lung cancer SH2 domain mutations autosomal-dominant hyper IgE syndrome inflammatory hepatocellular adenomas T-cell large granular lymphocytic leukemia T-cell prolymphocytic leukemia growth hormone insensitivity syndrome nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling targeting tumor-associated macrophages adoptive T cell therapy immune suppression STAT transcription factors JAK STAT T-PLL T-cell leukemia meta-analysis STAT5B signaling small-molecule inhibitors cancer models companion animals comparative oncology pharmacological inhibitor STAT5 signaling chemotherapy resistance myeloid leukemia heat shock proteins chaperones stabilization targeted therapy ovarian cancer hematopoietic cancers therapeutic targeting pharmacological inhibitors mTOR Bone Marrow Failure Syndromes lymphocytes lymphoma T-cells RHOA NGS MPN JAK2 V617F neoplastic stem cells |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557623503321 |
|
Moriggl Richard
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||